Paul B Manning
Director at Candel Therapeutics, Inc. (CADL); Director at Liquidia Corp (LQDA); Director at Verrica Pharmaceuticals Inc. (VRCA)
Purchase track record
Strong record. Based on 2 purchases with a full 90 days of price history.
86
Avg. 90-day return+32.9%
vs. S&P 500+27.7%
Beat the market100%
Paper profit on buys+$1.9M
Total bought / sold$20.5M / $12.8M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Jun 8SEC | LQDALiquidia Corp | Sell | 11,513804,798 held (−1%) | $63.13 | $727K | -56.6% |
| Jun 8SEC | LQDALiquidia Corp | Sell | 88,487716,311 held (−11%) | $64.28 | $5.7M | -57.4% |
| Jun 8SEC | LQDALiquidia Corp | Sell | 19,125879,210 held (−2%) | $62.62 | $1.2M | -56.3% |
| Jun 8SEC | LQDALiquidia Corp | Sell | 68,265810,945 held (−8%) | $63.83 | $4.4M | -57.1% |
| Jun 8SEC | LQDALiquidia Corp | Sell | 12,610798,335 held (−2%) | $64.42 | $812K | -57.5% |
| Feb 26SEC | CADLCandel Therapeutics, Inc. | Buy | 550,4582,763,527 held (+25%) | $5.45 | $3.0M | +82.4% |
| Nov 25SEC | VRCAVerrica Pharmaceuticals Inc. | Buy | 1,375,3803,958,189 held (+53%) | $4.24 | $5.8M | -3.1% |
| Nov 25SEC | VRCAVerrica Pharmaceuticals Inc. | Buy | 2,750,7623,348,372 held (+460%) | $4.24 | $11.7M | -3.1% |
- Buy
Director Paul B Manning bought $3.0M of CADL at $5.45 — first open-market purchase in our records; raises the stake by 25%.
- Buy
Director Paul B Manning bought $5.8M of VRCA at $4.24 — first open-market purchase in our records; raises the stake by 53%.
- Buy
Director Paul B Manning bought $11.7M of VRCA at $4.24 — largest purchase by this insider in our records; raises the stake by 460%.